Skip to main content
Signal8

ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

$ASPIPress releaseNov 16, 2026, 4:44 PM ETRead the release

ENDRA Life Sciences (NDRA) reported a Q3 2026 net loss of $1.5 million on operating expenses of $1.7 million, with no revenue; R&D spend fell to $176,000 from $432,000 a year ago while G&A rose on merger-related professional fees. The company ended the quarter with $1.5 million in unrestricted cash, $3.4 million in restricted cash, and $1.3 million in digital assets.

Key figures

Rnd q3 2025
432113
Rnd q3 2026
176280
Opex q3 2025
1370703
Opex q3 2026
1715163
Digital assets
$1.3 million
Restricted cash
$3.4 million
Net loss q3 2025
1595959
Net loss q3 2026
1528528
Unrestricted cash
$1.5 million
Cash used in operations q3
$1.8 million

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ASPI: ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update — AI Analysis | Signal8